<SEC-DOCUMENT>0001193125-13-066400.txt : 20130220
<SEC-HEADER>0001193125-13-066400.hdr.sgml : 20130220
<ACCEPTANCE-DATETIME>20130220095216
ACCESSION NUMBER:		0001193125-13-066400
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130220
FILED AS OF DATE:		20130220
DATE AS OF CHANGE:		20130220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		13625449

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d489596d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE
COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Form 6-K </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Report of
Foreign Private Issuer </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>of the Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>For the month of&nbsp;February 2013 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commission File Number 000-31062
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Oncolytics Biotech Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Translation of registrant&#146;s name into English) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Suite&nbsp;210, 1167 Kensington Crescent NW </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Calgary, Alberta, Canada T2N 1X7 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive
offices) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant files or will file annual reports under cover Form&nbsp;20-F or Form&nbsp;40-F. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form&nbsp;20-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;Form&nbsp;40-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting
the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits the submission in paper of a Form&nbsp;6-K if submitted solely to provide an attached annual report to security holders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a
Form&nbsp;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the
registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been
distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form&nbsp;6-K submission or other Commission filing on EDGAR. </FONT></P>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>EXHIBIT</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:35pt"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>NUMBER</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:55pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>DESCRIPTION</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">News Release Dated February 20, 2013 - Oncolytics
Biotech<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Inc. Announces Pricing of Common Share Offering</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Oncolytics Biotech Inc.</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Registrant)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:&nbsp;February 20, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;/s/&nbsp;Kirk Look</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kirk Look</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d489596dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit 99.1 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g489596img001.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">210, 1167 Kensington Cr. N.W</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Calgary, Alberta</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Canada T2N 1X7</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR IMMEDIATE RELEASE </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; " ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Oncolytics Biotech<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> Inc. Announces Pricing of Common Share Offering </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CALGARY, AB &#150; February 20, 2013 &#150; </B>Oncolytics Biotech Inc.<B> </B>(&#147;Oncolytics&#148;) (TSX:ONC; NASDAQ:ONCY) announced today the
pricing of an underwritten public offering of 8.0 million common shares, at a public offering price of US$4.00 per common share. The Company estimates that the gross proceeds from the offering, before deducting underwriting discounts and commissions
and other estimated offering expenses payable by Oncolytics, will be US$32.0 million. The offering is expected to close on or about February 25, 2013, subject to customary closing conditions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Piper Jaffray &amp; Co. and Wedbush PacGrow Life Sciences are acting as joint book-running managers for the offering in the U.S. and Paradigm Capital Inc. is acting as co-manager in the U.S. and
book-running manager in Canada. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to
an additional 1.2 million common shares to cover over-allotments, if any. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oncolytics intends to use the net proceeds from the offering to
fund its clinical trial program, manufacturing program and for general corporate and working capital purposes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The common shares are being
offered in each of the Canadian provinces of British Columbia, Alberta, Manitoba and Ontario by way of a prospectus supplement to the Company&#146;s base shelf short form prospectus and in the United States pursuant to a prospectus supplement to the
Company&#146;s effective shelf registration statement on Form F-10 (333-182260) previously filed with the United States Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus relating to the offering
may be obtained from the Securities and Exchange Commission website at <U>http://www.sec.gov</U>, from the System for Electronic Document Analysis and Retrieval (SEDAR) website at <U>http://www.sedar.com</U> or from the underwriters at: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Piper Jaffray &amp; Co. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">800 Nicollet Mall,
J12S03, Minneapolis, MN 55402 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Email: <U>prospectus@pjc.com</U> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Telephone: (800) 747-3924 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wedbush Securities Inc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">One Bush Street, 17th floor, San Francisco, CA 94104, Attn:&nbsp;SF Prospectus Department </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Phone: 415-274-6819 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: 415-274-6887 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Before you invest, you should read the prospectus supplement and accompanying prospectus, the registration
statement, and the other documents that the Company has filed with the Securities and Exchange Commission for more complete information about the Company and this offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of the securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration of qualification under the securities laws of any state or jurisdiction. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About Oncolytics Biotech Inc. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Oncolytics is a Calgary-based
biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics&#146; clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, its proprietary formulation of the human reovirus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>This press release contains forward-looking statements within the meaning of the U.S. Securities Act of 1933, as amended, and U.S. Securities Exchange Act of 1934, as amended, and forward-looking
information within the meaning of Canadian securities laws. Statements, other than statements of historical facts, included in this press release that address activities, events or developments that Oncolytics expects or anticipates will or may
occur in the future, including such things as the closing of offering of common shares and the intended use of proceeds and other such matters are forward-looking statements and forward-looking information and involve known and unknown risks and
uncertainties, which could cause the Company&#146;s actual results to differ materially from those in the forward-looking statements and forward-looking information. Such risks and uncertainties include, among others, risks related to the closing
conditions of the offering and risks related to the Company&#146;s business which may result in the intended use of proceeds changing. Investors should consult the Company&#146;s quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to the forward-looking statement and forward-looking information. Investors are cautioned against placing undue reliance on forward-looking statements and forward-looking
information. The Company does not undertake to update these forward-looking statements and forward-looking information, except as required by applicable laws.</I> </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>F</B><B>OR FURTHER INFORMATION PLEASE CONTACT:</B> </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oncolytics Biotech</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kirk
Look</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">210, 1167 Kensington Cr NW</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Calgary, Alberta T2N 1X7</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel:
403.670.7377</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax: 403.283.0858</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>klook@oncolytics.ca</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Equicom Group</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nick
Hurst</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">300
5</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Ave. SW, 10</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Calgary, Alberta T2P 3C4</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 403.218.2835</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Fax: 403.218.2830</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>nhurst@equicomgroup.com</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dian Griesel, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Susan
Forman</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">396 West Broadway, 2</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">New
York, NY 10012</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 212.825.3210</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fax:
212.825.3229</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>sforman@dgicomm.com</U></FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-2-
</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g489596img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g489596img001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`-P$"`P$1``(1`0,1`?_$`+D```$%`0$!`0``````
M```````&!P@)"@4$`P$!``$%`0$!```````````````"`P0%!@$'"!````8!
M`P,#`@0"!@<)`````0(#!`4&!P`1"!(3%!46"2$B,4$C%R0E47$R,R880E)#
MM39V-V&!D:'18B<*&A$``0,"!`0#!00&!P@#`````0`"`Q$$(3$2!4%1$P9A
M<2*!D:$R%,%2(P>QT6)R,Q7Q0K(D-#46X8*2PF-SDV0V)S?_V@`,`P$``A$#
M$0`_`-_&A"CUR2Y2X1XFT!?(V;[HSJT-U*MH>-(47]EM4FDEW?1ZM`-S>=,/
MQ*(=70!44"F`ZRB9-S:I=ZWW;=@M#>[G*(X@,LW./(#-.Q0R3&D8)5,K?Y$?
MDAYGN5S\">*C.B8O4<*-V.9<S>*JF_2(82>8S6E7L34RB`"!CH,DYTR8_03B
M.O.!W?W?W%*!VO9=.SK3JR##SJ:>ZF'-3C;6T`I</]?(+OEXY_//)E]5><S<
M'0[Y3]881M%Q)FB)_P"T"'6WP@=MT[_3Z"8-OS'4AVS_`)HN]?\`,;8.Y``#
MR_AG[4WU+$9,=[UPY'D;\U7$,IIW/>#*!RJQE&E[LW8<6HMD[$RCT!`[AV7V
M:Q8R;,"(E$3*N:TL@7\3&*'UTT=V_,G8`9=UMH[ZU:,3'IJ!S]-#7S%/@E-C
MLIL`XL>>>2LFX8?(SQVYN1B[;'<P[K.28AIY-EQ+<0;L+C&)I=)'3V,!)51E
M9H9!<1(9RS.8R0[`NF@8P%':=O=W;5W&TMM'%EZT>J)^#Q^L#R4::VD@^;%O
M/@I[:U7GFHZ-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&
MA"-"$:$(T(1H0C0A&A"-"$:$)DN1F>Z-QDPQ?,W9$<F1K5%AE)`[-N=,LA.2
MBYR-(2N1)%!`JLK/RRZ35`/P`RG4;8A3"%7O&ZVVS;?)N-T:0QMKG2IX-]I2
MXV.D<&-S*HJX6\1;O\C>1%/D#YX-U)VF2SM8O'[!+L7'L]"JL7AQCY%[%JF`
MAZ8V73'Q6IB@:<<E4>O!41.DFIY=VWL-YWA=_P"JNZ/5;%Y,$%"&AH/I)YTY
M\<E97,S+9GTUORQ/&JT;,(]C%,FD;&,FD=',&Z+-BP8-D6;)DT;IE20:M&C<
MB:#9N@F4"D(0I2E*````&O86QM:T,:*-'`8#W*K))Q.:]FG%Q&N4XC-"I4^1
M#XT"WMP;E9P[*?$G+?'3@]P:JTGH@4,H+1Q!<+MG+=H";-&[JHI&!!UT=N2Z
MA:O2J$5`Z?F_=?9S9G?SWMX"WWZ#UU;Z0\#$@TS/AQ\\YUK=:/P9?5"[GC12
M9^-CG"QYL8,&<GFZ$%F?'#U"G9FJI$3,_#L::)P:V)DP4V59Q%G(V54(B8`%
MJZ2<-Q_N0$USV=W,WN+:^M/Z+^$Z)6G#U##4!P!(35U!T)*#Y#B%8EK8*,C0
MA&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$(T(1H0C0A&A"-"$:$
M(T(1H0C0A9\OEW>2G(OE)P?X`1CYVWKF1+@CDK*";%40.>OMG[F+:'<$*/X1
M=>BIYRGO^"IDS?B4!#R?OY[MWWO;>U&D]&>3J2CFQIX_T<586E8XGW%,0,%?
MM`P4/5X2'K=>CFL1`U^+80D)$L4@091D3%-4F4<P:(E^U)LS:(D3(4/P*4->
MI0016\;88@!&UH:`.`&`'L"@$DFIS77T\N(T(1H0C7#7@A9W#1*?";YN(%M7
M$RQ.*N=5->J24,V*"<>E>G9WZJZB*!0*@DO[[@DW(=(;D)-JE#Z&VUX\8QVU
M^9#6QU;8;DT@MR;J=C7E@X%6)/7LBYV,C#\/Z%H?662;I*+KJ$1013.JLLJ<
MJ:22291.HHJH<2D333(41,(B```?77L!(8"78-"KDBJ;D_&N11?AC[(5(O0Q
M78"4]G6N!LWIOD]SQO/]%?O19^1V3]ON=/7T#MOL.HUO?V5VYS+66.1[<PUP
M)'G3)*<Q[,7@@+VV^^T;'S!M*7RY52DQCQX2.9R-NL416V+J0434638MG<R\
M9-UWBB*)S@D4PG$I#"`;`.ESW=M:M#[E[(V$TJX@"O+%<#2[(52I34(J0BB1
MBJ)J$*HFH0Q3D.0X`8AR&*(E,0Q1W`0^@AI\.!RRYKBY,]8J_58MQ-VB<AZW
M"LP`SN7GI-E#Q;4H[[&<OY!=NT0`=OQ,<--33PV[.K.]K(QQ<0T>\D+H!)H,
M2F5B>6G%J>E/1(7D?@N5F!/VBQK#*]&<O3J[]/:3;I3AE%%!-].DH".^JYN_
M[(Y^AMW;ZO\`N-_6EF*49M=[D_Z*R3A)-=!1-9!9,BJ*R1RJ)*I*%`Z:J:A!
M,0Z9RB`@(#L(?75J'-<-0/I/Z.:;2)O&4,:XR9)R61\@4J@QZH&%%[<[3!UE
MLL!/H;LK3+YD1;I_/I$=M1KF_L[)H?=RLC:?O.`_24IK'.^4$^225(Y&\?LF
M/RQ6.\WXEO,J<W0G%U/(E2GY)0W^JFPC)9R[4'Z?D0=1[;>MIO'].UN89'\@
M]I/L%<?8E.BD:*N:0/)/-OJQU`X!-I(.<A4)E;&5!>7:I-+U)-O-CJ6YLD,W
MMC]ET.%?,95Q5Z28=->TT5-W"(F+TI''?8H[1_K+9LXM72,%T14,J`XCR)J?
M8E:7:=0!TI8:E)*0%NROB_'\A%1-\R-1:5*3I1-"1UMML#7'LP4JZ;8PQ;:8
M?LUI#H<+$3'M`?8YR@/U$-1)[ZSMGB.YE9&]V6IP%?*N:4&.=\H)2^`P"&X#
M]!#??Z:E!P-",CEXU24AQR=C<+B&._?]*_<`Q!4+10M,$-Q%,&GJ`J>V0?\`
MK705@'?$>QL"/W_V?KJ+]?:?4?2=1GU/W:@N_P"$&OP7=+@-1&!7)M>;<,T*
M6&`O.6\94N=!LB]&%ME\JU=EP9N1.#=V,;+RK-X#9P*1NA3HZ3]([".PZ9GW
M7;K23I7<\4<O)S@#CX$I38WNQ:"4G!Y/<:P`!'D+@\`'\!'+%#`!_J$9_P"N
MFAONS$5^JM__`"-_6E=&7[KO<4XM/OU&R%'+2]`N=4O$0V=G8.96GV*'LL:W
M?III+*,EWT,\>MDG::*Y#F3$P'`IRB(;"&\ZVN[6\89+61DC`:5:0X5\Q@D.
M:YIHX$%?)7(N/T+DWQTM>*@CD!VS&1:T96R0R=O<QX(K.!?-ZV=X$RLS!NW4
M4[A41)T$,;?8!'277MHVY%DZ1@NW"H94:J<Z9K@:XM+J'2$LOP^HZDDTQ*XF
MROV:L/8J`@Y.RKCK'G=("B);K=:Y6%%B&^@'12F9)FJJ0?Z2@(:@W6YV%E_C
M)HXOWG`'W9I;6/=BT$^Q?&AYQPOE)04<:9;QID!<"&4,VIEXK5E<E3(`B=0S
M:'DWBY2%`-Q$2@`:3:;MMU^XLLYX97#,-<"?=FN%CF_,"$Y+U\RC6CF0D7;5
M@Q9HJ.';UZX2:M&K=(HF57<N5SIHH(IE#<QC&`H!^(ZG22-C89'D!@S)(`'F
M2D@5-!B5&MWS7X?,)4\&]Y18`;2Z2HHJ,%<MT8KA-8IND4SE&;V*<#?381U2
M/[EV*(ELMY;!P-#ZPG!#*[)KJ^2?NL7"I7:-+,4VT5VVQ!Q`"2M9FXR>CCB8
M-P`KV*<NFPB(?7;JU;P7-O<LZEN]CV<VN#A[P2D$$&AP*4>GUQ9^\CB4O_V#
M<%C+;`V-QM?A!^1_=^9[0RQOXV_T[G=!7_OWUY+>T'YJVAES^D=I\M(J!_O*
MR;_EQI]Y:!->LJM1KJ$:$(T(1H0L_ORKB`\_OBE)$#_B7]W')@[>W?"+]_8S
MWWV^X$MBK[?E_:UY+WW_`/)]CZ?\?ZG'GIJ:?%6-G_`EKEI^Q7H9%^N/[U_R
M=9_]R/O_`!UZ=?FEE-RZ3_[)4!OS#S6-3X_<'<AJGQU><\.&C^0?YDP]E.UT
M_*.(#=;N#R_B)M#5>P'CTHA$R9Y"5C!D%S"U)_$*DZ5F9B.T2%6^>.U=KW:W
MV=W=';9+MPAN)&R1<)8P:TQPPJ</<KJX?&Z;Z>X%&EHH?%2S^3_E_B[G'\=F
M(LHT+>-G:UR-I\3DG'DHLDI8L=VES2[R@I&RB)DTU',:Z53.9B^*0B3I,-A`
MBI%4D[SO?N*R[C[5M[RV.F:.[8V1AS8_##G2N13-K;OAN"'_`"%IH>!6HFI_
M\*UG_E^&_P!VMO\`UU[=:_X:,'[C?[(56[YCYK-KPRC&ORA\S^3]ZY>B\NU-
MX^3J,'BKCM-2#Q+'M;(\LUHA6TA+5!)=!G-OHEK5B@Y4=)J>2^<F,MU%(DF7
MQ_MZ,=[=QWUUOVI\%JX-C@)(8T$D`N;7$X5QYJPG:VWMV=,#4_$GBKSISA3P
M^LD4UA9KB]@)Y&,3HG9M0Q/2&H-3-SE42["K.%;KI%`Q`ZB@8`/^!@$!'7IY
M[=V)P`=9V^'[#1^@54+K3?>=[RG8R-.*8UQ-?+-6H=NNK0<>6B>@*\T;@BS6
M4JU;?2$5#-FC0J8)-E#L4T")I``%*(%*`?34V\<;6QEEA`U1Q.(Y>EI(!\$E
M@U/#>9"S[_#KB7'G-.&S5RWY6Q4/R%S8ZRLK6F"N3FJ%MAZ/"(UN%G4FM<JD
ML#JO0[=VXFSD0*1L!4&S9--'H`#]?DGY>6%OW+%<;[O[1<;@9RT!_J:QN8TM
MRQ\AEC4JQOZV[FPQ8`#,<58]S8X#\5<B\?<KR[?#V/,>7JEX^MMOI.2<?U>%
MHMJJMAJ\$]G8M\G,UEK%.'#$'+`I%T%Q42.B8VP%/TG+L^Y>V=EN=IGF;#'#
M<QPN<R2,=-S2`3@6TY*/;7,S9FBI()H:X_I34?"3R+RER(X?N7669R2MD_C;
M(<KCV,MTPJ=U+S==:0%<G8M.7D%`[TI)0X3AVIG*HF65233%0QC]1AKORRWB
M^WCM\F_<7O@E+&N.9:`*5/$CFE[A#'#/2+Y2*J+^;2)__H)XUG$A.L,+)@!^
M@!.'^#\N_0#;;A^.J7=O_P!6LA_Z_P!A3D?^7/RS6B7\M>O-^7%5BBMR^X>X
M=YHXHD,7Y9AR&53[SZF71@W;^Z:#8Q1,DVG*^\5+OT"(@5VS./C/D-TU"[]!
MR4>_]O;;W#9&UW!M:8L<,',=P+3GG[T[#,^)VIN7$<U0W'\T.??"LDK\<=DI
MB68>2,@ZKU5XE9<5>MW,?+T:?</8R/FIM.47*:<)`,F!Q8"].4[)5!5&0%1)
ML4RGE3>X^Z^W*]GSQ]?=WD-MIJU;H<:-)'$@>5,E8=""8&Z'IAXCQ5M/`;X^
MX#BI&S&3\E2Q<K\L<H"XELM9CF#JRDB#V55*\?5JK/GY/+:P:*^P+K[$6D%"
M`8X$2*B@EZ#VMVI'LC'7EX[K;W/C+*<2"<VL-,&\^:A7$_6(`%&#(*6E_P",
MO'3*U@&V9.P3B/(=H%DVC1L5UQY5;--C'LS*F9L1E)B+=O1:-3+G%-/KZ2=0
M[`&XZO[K9MJO9>O>6\4LU/F<T$X98E--ED8*,)'DL_OQL<<\`7GGG\E=0N>%
M,66NJT3(AF-)K=BHE;F8.I,AO]Y:BTKD7(QSEE#M_%9HI]*!"!VTBE_``#7D
MG9>T[;==T[Q;7,$4D$;VZ06@AN)R5I=RR-MXM+B#3.IQ6C?'F+,:8C@UJSBR
M@4W'%=<2"\LO!4>MQ%7B%Y1TF@BYD5H^%:,VJCY=%JF0ZHE$YBIE`1V`->Q6
MEA9V$9CLHV11DU(:*"ODJISW/-7DD^*H5O1$_P#]#N*S"4G7^Q9OOZ0Z_P#I
MCD#8.K;?;ZZ\JNQ_]NP$Y?2#^R5/;_ESOWE8K\IO(O(?%[AED;)F*^IK>'$A
M6J9#V`&R;L*@-OE4HIS:"H+)JMS.HYL<Q6HJ%%,KM5(Q@$`Z1V/?>\WFQ=MS
M7U@*W-6L!I73JPU>SGP3%G&V6X:Q_P`M5'_XV.$7'67XVXKY!Y.I5>S[F_-5
M69Y#NV4LOM$,FSBDA83*/`AXI2V!+MHEI"$,#<PHD*NJL0YU#B(@4E9V?VWM
M,FS0;G=L;=;C<,#WR2$O)KP]51AE2F=5VYE<V8MC]#6X`#!6-4_B]QPQ[>QR
M=0L%8GI60!C7,1[NJ=#K=>FRQSTQ#/&R;N)CFAD@=]L"JF+L=0GVF$2_36PM
M]FVFTN/J[6WACN*4U-:&FGL3+II7C2YQ(42?E"X;98YI8+BJ#B7)R-(EJ[9#
M6:0J,RXD6--R>W28*-VU=M,A$`H^9IL7!^^U,*3AN*P_J$`0(HGG>]>W[WN+
M;1:V$_2D8ZI;PD'W7'@/%+MY6POU.%:_#Q4(J_:[%A&B,J+G3X0HQ:N5R-3C
M9J>P/7<0YAKD@U8I$1<3"$*I'N+.X*Y*F*PBZ=+N1$?O4$VXZR\5Q-MELVTW
M3MUKHV-`+XFLD!H,78MJ:YYJ2:.<713$$\ZA3B^.G,O`O)5<R#&<+:?#8N?-
M9IK/91QJ-,/0[9&2KXJL>SD)B&,9=JX9E,Q5;IBS76:ME"&3V3,;8VL[2W/M
MF_@D;V\P0N::R1ENEP/,M)^*CW,4T3_Q36O'FK*-;%1EGS^7YA+\>.2G"3Y`
MH>/=NX/&-T;XZR<+%,W66O.I!>69)+G+^!9:"D9YH03?3O"D7\3`&O)N_P"-
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MVVX:]:N(NM`^($#6UPKGF",N*K@:$$\U!+XYN#SW@=B*W8N>Y'0R8-FR$]O*
M4LWK1ZP5@1Y!PD/Z<+128F1<'*,/W.[UD#[]NGZ;CF>T>VO]+[<^Q$G5<^4O
MK2F)\."D74XN)`^A``HHD\TOA7QYR4R4_P`I8GR.I@.8N3A!]E6OL*T:?IUX
MF&+D'<?9@A&TW`IQ=@!8RAG!P%5%PH?N]!%C*G5SO<7Y;V>\7OUUC,;8N>'2
ML`K'(1D[3_5<.83D%V86EI%:\5=7$L!C(J,C!5[PQ\<R8BMT]'=%HV3;]T"=
M1NCN=O?;<=M]>DQ,Z<0BK4AH%?(`?950SB:JM7+/QJPS_.4ERBXOYEN'%3/<
M^*Q[C*U:*BK7CO()W!TEG9KICN9,WCWJDDX0*JZ%)9--=<H+&3%?=0<;N'9D
M<FXNWG9;F2PW*3YRP-<R3]]IP-5(9<D1]*1H<P9>"4K?"WR22J(15@YLX>K[
M`/TE+!1N+K12VN$=MCJ)DM5^E*TQ=F#?8Q6:I"C]0+^6I'\N[OD'3=N5NR/F
MRWH[#]YY;\`DET&;6GWJ?L+'2#2`C(N>E?<LFWBVK*8FEXYG'>NO$VQ$7TBM
M%,P\!EZBJ!E#()!V2=8E*'2`!K41LD$+63.UR4`<2T#5S].0KX)FN-1@JO6/
MQN6G`F3+MD_@EGY?CLADITG(7O#ULHK'*6&Y>317<.$7\1#N):"FJJL@=TH5
M+QG1^RFH9-(2([)!BF]G3[7>R7W;-V;,3.K)$Y@DB<>8!(+3XA2C<B1H;,-1
M&1XKVY*XC<Y.1-5E,99PYG4BK8MLK88RYPN!,&C6+1:X-;8'T*M;K;=+(M$,
M9)'=)<&Z`@HD82G`Y!$@N7FP=Q[O";+<MPC98N^801:7.;]TN+C0<Z9KD<T4
M3Q(QE7#FIO<=N.V*^+.*H##N'8$T#3H`SESLZ<G?R\S+OS@K*3\])J@562FI
M-8H&55$"E`I2D3(1,A"%T>S[-8;%9-L-N9H@;GS<>+B>)*9EE?,[6_-00Y'_
M`!X94RGS-J/,_$/(:"Q-=Z51V%/A(N=Q4ED!DFH@WLS!^_7*YM,.V<$>QUE4
M(5,R6Z1R@8#".VV8W?M*^O\`N.+N.PNFPSQ1AH#H]7/Q"?BN0R$PO;5I3L5S
M"WR),[#`O+/S<Q=-UII,QCFP0S#BS"Q+Z7A$'J*LI%LY3WVZ]-<OV1#I)N.T
MIV3'`_2;;8;"#;^[1*QUQN$#H*^H"W`)\C7!-ZH---!U>:L'_+6L.5$PJV,X
M<`7F8>=O'_F8GD]"!:X0B8N,6Q^:K'D%[&,8]M;P%4[$$VT)&@N-F`HE%HMT
M]G?<>KZ8S<NTV[AW/:=Q=6AMJ>BF:EQW)CMW04^963A^&MDWY5$7Z.E(5=W%
M#@J\XT\C^6.?%\DH6]+DS:?<:%93K!X92GD]R6&?%HK*FF9`)DVTZ"0'!!M_
M==6WW;!CNW^U?Y)NU[N@FZ@O'`T(Q;0DY\E)FN.JQC*4TBBL1UL/!1E7'/<"
MG<U\B]4YX_N8BW:5FA#3/VT]L'47=JC6+!7/4/<_K)"(I_SSO=OPC#^GT]7U
MW#&R]JNE[OC[HZU"R$,,=,Z`BM?:I`N"+?H`8$J<F2L;TC+]$M&,\D5V/ME(
MN<2XA+'7Y,ACM)!@Y`!$O40Q%F[A!4I545DC$506(51,Q3E*(:B]L[>_MGVE
MTT/MY&T<T\C]O(IECW1N#V&CADJR\=?'YR/XLMWE9X<\S'M;Q.M(.I"+P]GS
M&C#+D!5SNUCN%V]9LK&;JUABVBRZICG3)L4YQ$Y^M0QC#BK#M/>=B8;;M_<2
MRP/RQ3Q=4,QJ=+@YKO?@I+IXI#JF95_,&BE-B3%7,6)N\;;,V\K*E<ZXS;/6
M[O%^/\#P=*KLH=TAT(NW=GE[)9[<1Q'N"E42[*J)#;"4Q1*80U>V-CO\=TV;
M<KV.6``@QLA#`X\ZEQ((\Z'DFWO@+:1L(=S)2IY'8GS_`)+1J[C`W)I_QYE:
MXX?.GZ1,9U'(\+<#N4TDFK:P-;(9%VW9L"E.)"M54P,=3<X&$I=GMXL-UO0P
M[9>&U+3B.F'AWF30I$;F--7MU!1L_9SY27+0\.YYF\>6*"I3(FM47QC>'M*2
M9OM[[>/>7T]:*[*4=P$R)DP-_H[:J';=WLYKHQN%JVN3A!ZASPKIJG==MF&&
MOG@EIPI^/S'?#9WD2YMK=:<JYER^^-)9,RI;P:,GTVNK)O)IRUBH*,`(^%CW
M4S(*NE@ZUUEE3%ZU!*0A2O\`;?:=GV\^:Y:]\^XW!K+*[`N\`!@*%=N;I]Q0
M'",9!3\UK5%3,\@\%T7DGAR^83R,T,YJM\A%HMTN@!/4(=\0Q'4/8(A10IBH
M2\#*H(NFY]A#N)`!@$HB`UN[[7:[S82;?>"L,@]QX$>26Q[F.#FYA4,\/N5U
M]^,G))^!'.I9Q'8O;OG2_'O/JJ3I2IA6'SXXM6;QZ8JG13'+A43%4ZA4K[PZ
MC9T4K;MJI>5=O;]=]EWO^E^Y\+#4>A.3Z=).`KRKPX*RG@;=L^IMOG`Q''S6
MCR*EHN=C6,S"23"8B)-JB]C96*>-Y"-D&3@@*-W;%\T46:NVJZ9@,11,YBF*
M.X#KV..5DC!)&0YA%01B"//)59!!H<"O?OIS-%$;Z3J%:<5Q4@_(3\F"T0^'
MB'PC.?+G*K(RZU.5D:.))IEB_P`TAV[\Z4BV%2.<75NW,80#N>/"E*9R\.04
MRIF\T[L[T<R0;!VQ2YWV:K:MQ$7`D^/CD/&N$ZVM"X=:?TPCGQ4N?C@X01/"
M+`Z%4D'+:?RU>W:-OS%;DCG<!*6A5`2H0C!TK^NO!UA%8Z*!SB)G"YUW)MC+
MB4M_VAVS'VWM7TK_`%WDIURO.9<<:5X@$T3-S-UI-0P8,!Y!3>O%@4J=+MUJ
M1;)O%:S6)^P)-%5#(I.E(:)=R1&RJQ2G,DFN=L!3&`!$H#OL.M'>S.MK22X:
M*].-SJ<]+2:>T@!,M%7`'B54Q2/DJR.\I7&#)]\QE4(*@\@9JB1<]-++VZLP
MF/4;\ETQCA&W2[658V]UYYB(-VZ#-OYIC@(*(E`3!A(.\;DV]I>W$,;;>X(U
M$ZFAE<,"XG5CR"D26^@D`@T5QVO0P33FHJC.VSU)K\PI7C(-?CRQ$=QSB<WD
MM(2"XRJLC(Y&D:.>"-&"@#4K!-NQ!<%^YUBH82].WUU2LW61V_NV4M&EML)=
M6.)+M)'+[4[H'2ZE<=5**3.KU-*"E*Y+Y*S+DW/U'QU$8RHK/`-_5QO(DRO)
M6!2XVJ3;P["8-;&E8A1BP@*')IR`$C7JJ[L[XJ2B@$(4`*.7M=XN;Z_N(8A#
M%';R=/\`$+@YQ`!)#10:<<#CQ3Q8UK14DDC@G`XD<DEN3%)O,\^JS:LS&-\M
MWG#DZM"3)[-2K/,41RU;O+30+,=A&'FZI)^8`)*'03427351-U"GU#)V+>#O
M$$DSF:#',YA(J6NT\6UQ29(S&:%/]=`O0PX!CP]33L'EM]S7-*86A@8?J>4`
M$@UD'WF"/3V_NZ/QW_+5M<"YTUM='4_:K3X8I`IQ45.&.><Q<E<=1>6[="8O
MK52E)C(E<3A:NZM<C8$9.B7F;I(.CR$J5O&'92"T`LX$@)=Q,JI"=0B!AU1=
MO;I?;Q:_6S-B9%K>T!NO55CBVOJPH:)R5G3=IS/ZU-<=:1W#S32K0XE\S,L<
MFXFIVIQ1ZG3:]8+9<H5T`Q-UD62$=3K7-5U46EU.LS@UI63)#[HD,V!,KE0$
MAW$-QQVQ=P76\,;,8XXP9'-R/]5Q`H2[,CP*?EBZ>1J%9AK9A,*%EWY-6D.3
MW^5FA5^I0E@88P8Y5D[[EB6D(BN3$;)33B$0KN.X&*33DKM-,%&YEI)4';5O
M'IB0INLYRAK,7.]3C>?Y);-C9*V$2E\I(:X$THP"A)!^;'!.AC>GU'',X`9J
M3]#>VI]!">YO*8_GD7[UNNXH:TDK`]E)79L3IE55WC=^5(0[Z9CG`AA^@B&K
MZV,KHZREA=S826_%-E+(P[`(_P!`"/\`7L&G)7.8TO'`$TYX'[4*IYI\E4\X
MX/VOE2;!5L/8Z]"9#DD8QK&2R^,72M,O,[4FJJM[[8+)Q3AO$E5=+@WW06[B
M8%,!`$<3%W?,_M]^\OMI>JS5@&.T'2_36M:T4GH-ZHCU#2?U*T>LRQY^MU^=
M51(W4FH2)EE&Z9Q430/(L&[PZ)%#`4RA$C+=(&$`$0#?6TMI>O;LG^^QKO>`
M?M48BA(7<T^N(T(47+AR!E*SRVPOQN1KT:ZBLIXJROD1[9E9!PG*1+K'4C4F
M36.:1I4#-G362+8SF54.H4R8IEV`=QU0W&ZR0[Y;[.&@LF@D?JQJ"SX43@83
M&9.`-%*/5ZVM*'--JN*X<YK10>3.:,9SN('4W@W!\/B9YD#*-*?/K!<Z.&5H
M"5G&-KL>.V\<=Y(8\AS0CA*1>1JCAW')]+A1N='N&3Q]QW+-;[W/M[X*[?;L
MC,DK22YO4^6K*8CF1D,2I`A:8@[5ZR<D^7$#DA_FDQO:LBI1\"RC8?,&5,=P
M+NM31I^'L->HMH<0L':&TB*229_<,:1-R)4^I,O7]IA#5GV[O(WVQ=>M`#1,
M]@I6A#3@17G5(E8(W!H-<*KZ\L>20\:*;2IYO4PM$ID3*%.Q-"+RDPG5Z-5I
M:YN'"#6TY'N"K.03K%.BP;&[R_85.JL9-$@`=0!`W[=W;/;QRLC,CY96QC@U
MI<?G><PP<2%R*/J&E<A5.'C^6RF[ESHWN8P](QB\.5VR2Q^O8O5RO>^B4YSD
MF7KMN\ARHJ;`N0$CBH)?L`!U.M7W#W$3O@<VF&@N)^)."213@4\>K!)1H0HB
M<S*/P]R-B].G<R9K%==I$R]6;UN;R5=:[CYY&6(6P]+RDVJ<E(AQ'V!NC]VS
M5414('2J0Z8B4<WW+:]N76W&#N-\#+)QP=*]K*']ESB*%/P.G:^L&K5X5*IK
MH/!;ESA!@XN'Q6<^J;EC#*S]=5GCVU6BNW"K)K@J(JL&DI$H6['CYR`!LHL@
MA"KF$?N^NYM>=VG:^_[;^/V/ND<]AJKH<X/;Y5!+?BI;YXI,+IA;)SI1.D7,
M/S^18>DN.,_':><I[(^X$96LD06'^SY(D2S-')?]H[-B`'^K^6K!VX?FHT%@
MM+,_M`CWTU@)&BP^\Y(^U\8/EUY,14C_`)N.6&.>+.%B-SJVR'QT_CV2A841
MZGB<B[KJD2U59%2^A_4;&HW#_2(8/IJ--LWY@;S&1OM]'8V1'JZ9:,.5033"
MN9HEQS6L6$3"]_BIR?'M@3X[<`ED*SQ5RKB',>6'42"]RNT5E.@9'R?)1::I
M"KF.WJTHZ&LU@'HA_#LVS=N)^GO&54`#ZU7:NU]I[9J@V:>WN-PI^(\2,?*>
M=:.)`_VIBXDNI!68.;'P%"`K2=;=1%XY#P/`>^J^)Z9XCGU'S^SX'@=D_F>;
MY'\/XGC]7<[GV=&_5]-](D#"P]3^'0UKE2F-?"F:Z%&.FAPE]=@_V^'BS[F%
MRG[:]G#B49WS-A[7H7HO\>#G;?I\?[OZ-5$+-@:6=$VNJOHH8SC^SX^6*55_
MBI3AJY%."0DD0*)[Y6[?M/\`<KVNCY'0,/[X]E>JK>/W]OY][6]<[G1U?PGE
M]6WZF^F*6WU%?1]5I'+5IK[Z5]BZE=J0N)@<FDXNGGT@S&.!PM01R9D?W(4H
M"=A]'!13M`0;*8LD,7W>K8/[GJW_`#U67;-H?(/K>AU1]XM!R\2#E\%T:N%4
M[%.]G>V8?V![:]F^(7V_[/\`2_;/@=9^GT;T7^5>)W.K;L?9U;_GOJ7`+71_
M=M'3K_5I2OLPJ@UKC6J4PZ?XKB2%'"AA7D?VV&I>TQ>RWC>R!AAKH27JCOUW
MQ_0?Y:#WUOR/+Z?O\KN=S]3JU'MQ:B/^Z:.E4_+2E:XY<:Y^*Z:U]6:5PZD$
M`KBBG"EX/#/L/;@\5/=/KI/2_0S8C"?]S>?^GX'@#ZAZ[ZI^';_B/(_]^J1K
M.WG2M,9M.N'8:3&#J\*<?BE'7QJI6ZNQ0#!)33Y5#!HLHH,W#BGTX72H0?[I
MC42M/.Z"][T@UL$$@=]O;J[`]?3MO]-0;MNW%P%\8==#37IK3C2N-.=%T5X+
MN8Y#&05L@8D]B^T0>N@)^W8P`USU$!)YW2-;$8T7W5T][_:;[=6G[9MLV("T
MT]'AI((^"#7BEV8`$!W'8-AW_JV'?_RT\X-/S9(":M$,(?M>^\?]J_V6\.7]
M2[(U+]KO3_477KWG='^%/#]7[WE]S[/)Z^Y]_5J#&S;?I?P3#]%0_*6Z*5]5
M:89YGFN^JO&J<UIXOBMO!\?P?'1\/Q.WXOB]LOC^-V?TO'[.W1T?;T[;?34Y
MNG2-'R4PIE3A1)7HTI"-"$CGQ:#[U@/4AJ/[C>C37M?SAAO>OM[NL/<?H'D?
MSST;O^-YOC_H=?:[OUZ-17-M/J&%VCZD-=IQ&JA^:G&G-*]>DYZ:^Q+'4I)2
M.C0H`VVV^CC4/??B0'OOTP87W;X'C._:WNWQ?YQX?A^1X'F?9VNYV?MZM1`+
M(SR:>G]5I&NFG5IX:N-//!=QP7BQO^U_MO\`^(O87M#U24_Z<>WO;?K7EG];
M_P"&?Y9ZIYW5Y7^U[N_<^[7;,68@`L.G]+C3ITTUKC33AGF@UKCFN_:/;'MZ
M7]Z>@^U/"5]>]T>G^WO3M@[_`*OZM_+?"V_M][]/^G2[@6YC/U6CH\=5--/&
MN%/-`K7TYIJ<7EXSA+N/V7'!WKHQRAG7[8GH9I;T?R$.Z"_M81>!%^5VNH!_
?1[G3^>VHEFW:@?[@8*_],M_Y4IQ?3U5HGUU9)"__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
